AlloSure (CareDx)
HAYES, Inc
Record ID 32018000081
English
Authors' recommendations:
The reference standard for diagnosis of renal allograft rejection is needle biopsy, but it is not typically used to monitor for rejection due to risk of complications, patient discomfort, and cost. Rejection results from injury to the allograft and cell death, which are correlated with elevated plasma levels of donor-derived cell-free DNA (dd-cfDNA). Current methods used to monitor for renal transplant rejection are indirect measures of renal function that are not specific to transplant rejection. Tests that measure dd-cfDNA may offer a noninvasive, more sensitive, and specific assessment of allograft rejection that is safer and can be performed at more frequent intervals than needle biopsy allows. This report reviews 1 such test, AlloSure.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
The report may be purchased from:
http://www.hayesinc.com/hayes/crd/?crd=77406
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Allografts
- Biopsy, Needle
- Cell Death
- Cell-Free Nucleic Acids
- Graft Rejection
- Humans
- Kidney Diseases
- Kidney Transplantation
- Transplantation, Homologous
- Urinary Tract Physiological Phenomena
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.